A Phase 1 interventional study of Digoxin and Furosemide in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-07.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Main objective is to investigate mutual pharmacokinetic drug-drug interactions of digoxin, furosemide, metformin, and rosuvastatin when given all together as a cocktail
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
In addition, the following trial-specific exclusion criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 tablet (0.25 mg) digoxin as single dose
Drug: Digoxin
0.1 mL (1 mg) furosemide oral solution as single dose
Drug: Furosemide
0.1 mL (10 mg) metformin oral solution as single dose
Drug: Metformin
1 tablet (10 mg) rosuvastatin as single dose
Drug: Rosuvastatin
1 tablet (0.25 mg) digoxin, 0.1 mL (1 mg) furosemide oral solution, 0.1 mL (10 mg) metformin oral solution, and 1 tablet (10 mg) rosuvastatin, all together as a single dose ('cocktail')
Drug: Digoxin · Drug: Furosemide · Drug: Metformin hydrochloride · Drug: Rosuvastatin
single dose
single dose
single dose
single dose
0.25 mg digoxin as single dose (all 4 drugs given together as a cocktail at the same time point)
1 mg furosemide as single dose (all 4 drugs given together as a cocktail at the same time point)
10 mg metformin hydrochloride as single dose (all 4 drugs given together as a cocktail at the same time point)
10 mg rosuvastatin as single dose (all 4 drugs given together as a cocktail at the same time point)
Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz)
Area under the concentration-time curve of digoxin in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error. CI - confidence interval, gMean - geometric mean.
Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration
Maximum Concentration of Digoxin (Cmax)
This outcome measure presents the maximum measured concentration of digoxin in plasma (Cmax). Standard error presented is actually geometric standard error.
Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration
Area Under the Curve of Furosemide From 0 to Last Quantifiable Data Point (AUC 0-tz)
Area under the concentration-time curve of furosemide in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error.
Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00 and 24:00 after drug administration
Maximum Concentration of Furosemide (Cmax)
This outcome measure presents the maximum measured concentration of furosemide in plasma (Cmax). Standard error presented is actually geometric standard error.
Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00 and 24:00 after drug administration
Area Under the Curve of Metformin From 0 to Last Quantifiable Data Point (AUC 0-tz)
Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error.
Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00 and 48:00 after drug administration
Maximum Concentration of Metformin (Cmax)
This outcome measure presents the maximum measured concentration of metformin in plasma (Cmax). Standard error presented is actually geometric standard error.
Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00 and 48:00 after drug administration
Area Under the Curve of Rosuvastatin From 0 to Last Quantifiable Data Point (AUC 0-tz)
Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error.
Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration
Maximum Concentration of Rosuvastatin (Cmax)
This outcome measure presents the maximum measured concentration of rosuvastatin in plasma (Cmax). Standard error presented is actually geometric standard error.
Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration
Area Under the Curve of Digoxin From 0 Extrapolated to Infinity (AUC 0-∞)
Area under the concentration-time curve of digoxin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.
Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration
Area Under the Curve of Furosemide From 0 Extrapolated to Infinity (AUC 0-∞)
Area under the concentration-time curve of furosemide in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.
Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00 and 24:00 after drug administration
Area Under the Curve of Metformin From 0 Extrapolated to Infinity (AUC 0-∞)
Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.
Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00 and 48:00 after drug administration
Area Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC 0-∞)
Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.
Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration
| Milestone | ABECD (R1->R2->T->R3->R4) | AEBDC (R1->T->R2->R4->R3) | BACED (R2->R1->R3->T->R4) | BCADE (R2->R3->R1->R4->T) | CBDAE (R3->R2->R4->R1->T) | CDBEA (R3->R4->R2->T->R1) | DCEBA (R4->R3->T->R2->R1) | DECAB (R4->T->R3->R1->R2) | EADBC (T->R1->R4->R2->R3) | EDACB (T->R4->R1->R3->R2) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Received r1 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| Received r2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Received r3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 |
| Received r4 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 |
| Received t | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Area under the concentration-time curve of digoxin in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error. CI - confidence interval, gMean - geometric mean.
| nanomole hour per liter (nmol·h/L) | Test Cocktail (T) | Digoxin (R1) |
|---|---|---|
| Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz) | 11.549 ± 1.053 | 11.981 ± 1.053 |
This outcome measure presents the maximum measured concentration of digoxin in plasma (Cmax). Standard error presented is actually geometric standard error.
| nanomole per liter (nmol/L) | Test Cocktail (T) | Digoxin (R1) |
|---|---|---|
| Maximum Concentration of Digoxin (Cmax) | 1.262 ± 1.047 | 1.355 ± 1.047 |
Area under the concentration-time curve of furosemide in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error.
| nmol·h/L | Test Cocktail (T) | Furosemide (R2) |
|---|---|---|
| Area Under the Curve of Furosemide From 0 to Last Quantifiable Data Point (AUC 0-tz) | 163.614 ± 1.039 | 159.434 ± 1.038 |
This outcome measure presents the maximum measured concentration of furosemide in plasma (Cmax). Standard error presented is actually geometric standard error.
| nmol/L | Test Cocktail (T) | Furosemide (R2) |
|---|---|---|
| Maximum Concentration of Furosemide (Cmax) | 86.275 ± 1.046 | 82.990 ± 1.044 |
Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error.
| nmol·h/L | Test Cocktail (T) | Metformin Hydrochloride (R3) |
|---|---|---|
| Area Under the Curve of Metformin From 0 to Last Quantifiable Data Point (AUC 0-tz) | 1283.797 ± 1.034 | 1316.790 ± 1.033 |
This outcome measure presents the maximum measured concentration of metformin in plasma (Cmax). Standard error presented is actually geometric standard error.
| nmol/L | Test Cocktail (T) | Metformin Hydrochloride (R3) |
|---|---|---|
| Maximum Concentration of Metformin (Cmax) | 225.156 ± 1.045 | 229.171 ± 1.044 |
Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error.
| nmol·h/L | Test Cocktail (T) | Rosuvastatin (R4) |
|---|---|---|
| Area Under the Curve of Rosuvastatin From 0 to Last Quantifiable Data Point (AUC 0-tz) | 81.925 ± 1.070 | 78.016 ± 1.069 |
This outcome measure presents the maximum measured concentration of rosuvastatin in plasma (Cmax). Standard error presented is actually geometric standard error.
| nmol/L | Test Cocktail (T) | Rosuvastatin (R4) |
|---|---|---|
| Maximum Concentration of Rosuvastatin (Cmax) | 8.135 ± 1.074 | 7.801 ± 1.073 |
Area under the concentration-time curve of digoxin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.
| nmol·h/L | Test Cocktail (T) | Digoxin (R1) |
|---|---|---|
| Area Under the Curve of Digoxin From 0 Extrapolated to Infinity (AUC 0-∞) | 17.668 ± 1.039 | 18.303 ± 1.039 |
Area under the concentration-time curve of furosemide in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.
| nmol·h/L | Test Cocktail (T) | Furosemide (R2) |
|---|---|---|
| Area Under the Curve of Furosemide From 0 Extrapolated to Infinity (AUC 0-∞) | 156.382 ± 1.049 | 160.551 ± 1.052 |
Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.
| nmol·h/L | Test Cocktail (T) | Metformin Hydrochloride (R3) |
|---|---|---|
| Area Under the Curve of Metformin From 0 Extrapolated to Infinity (AUC 0-∞) | 1290.928 ± 1.033 | 1324.078 ± 1.033 |
Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.
| nmol·h/L | Test Cocktail (T) | Rosuvastatin (R4) |
|---|---|---|
| Area Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC 0-∞) | 97.385 ± 1.072 | 90.479 ± 1.069 |
Collected over Adverse events (AEs) occurring up to 192 hours after intake of trial drug administration in each treatment period were assigned to treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Digoxin (R1) | — | 1/28 (3.6%) | 0/28 (0%) |
| Furosemide (R2) | — | 0/30 (0%) | 0/30 (0%) |
| Metformin Hydrochloride (R3) | — | 0/29 (0%) | 1/29 (3.4%) |
| Rosuvastatin (R4) | — | 0/29 (0%) | 1/29 (3.4%) |
| Test Cocktail (T) | — | 0/28 (0%) | 3/28 (10.7%) |
| Event | Digoxin (R1) | Furosemide (R2) | Metformin Hydrochloride (R3) | Rosuvastatin (R4) | Test Cocktail (T) |
|---|---|---|---|---|---|
| Exposure to toxic agentInjury, poisoning and procedural complications | 1/28 | 0/30 | 0/29 | 0/29 | 0/28 |
| Event | Digoxin (R1) | Furosemide (R2) | Metformin Hydrochloride (R3) | Rosuvastatin (R4) | Test Cocktail (T) |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/28 | 0/30 | 1/29 | 1/29 | 3/28 |
The randomised set (RS) included all randomised subjects, whether treated or not
| Age, Continuous(Years) | ABECD (R1->R2->T->R3->R4) | AEBDC (R1->T->R2->R4->R3) | BACED (R2->R1->R3->T->R4) | BCADE (R2->R3->R1->R4->T) | CBDAE (R3->R2->R4->R1->T) | CDBEA (R3->R4->R2->T->R1) | DCEBA (R4->R3->T->R2->R1) | DECAB (R4->T->R3->R1->R2) | EADBC (T->R1->R4->R2->R3) | EDACB (T->R4->R1->R3->R2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 26.7 ± 2.5 | 28.7 ± 8.1 | 41.3 ± 15.8 | 42.0 ± 5.3 | 32.3 ± 9.0 | 45.7 ± 7.2 | 30.3 ± 6.4 | 33.0 ± 9.6 | 40.3 ± 7.5 | 34.3 ± 7.2 | 35.5 ± 9.4 |
| Sex: Female, Male(Participants) | ABECD (R1->R2->T->R3->R4) | AEBDC (R1->T->R2->R4->R3) | BACED (R2->R1->R3->T->R4) | BCADE (R2->R3->R1->R4->T) | CBDAE (R3->R2->R4->R1->T) | CDBEA (R3->R4->R2->T->R1) | DCEBA (R4->R3->T->R2->R1) | DECAB (R4->T->R3->R1->R2) | EADBC (T->R1->R4->R2->R3) | EDACB (T->R4->R1->R3->R2) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 30 |
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
No publications or documents are linked to this record.
Ran from Aug 2016 to primary completion in Nov 2016, 2 months.
Results were first posted in Aug 2018, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Digoxin · Furosemide · Metformin · Rosuvastatin